Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib in newly-onset type 1 diabetes mellitus
NCT07845955Phase 2Not yet recruiting
- Sponsor
- Huijie Zhang
- Start
- Sep 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in type 1 diabetes mellitus (T1D), sponsored by Huijie Zhang. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07845955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845955.